Core Viewpoint - MicroPort Robotics-B (02252) has achieved a significant milestone with over 200 global commercial orders for its TiMAY® laparoscopic surgical robot, indicating widespread recognition of its clinical value and safety [1] Group 1: Company Performance - As of the announcement date, the company’s TiMAY® robot has completed nearly 130 installations worldwide, demonstrating strong market penetration [1] - The stock opened over 3% higher, currently trading at 26.8 HKD with a transaction volume of 2.987 million HKD, reflecting positive market sentiment [1] Group 2: Product and Market Expansion - The TiMAY® robot has received commercial application approvals in nearly 10 countries, including China, India, and Brazil, covering regions with nearly half of the global population [1] - The system has successfully completed nearly 800 remote surgeries across over 20 countries, maintaining a 100% success rate, which underscores its reliability and effectiveness in clinical settings [1]